DDInter1327 DDInter1625
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
Rubella virus vaccine is a live attenuated virus vaccine for active immunization against rubella (German measles) that is subcutaneously administered. It is prepared from RA 27/3 strain of live attenuated rubella virus. Rubella is a common childhood disease, caused by rubella virus (togavirus).
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Satralizumab
Olaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Etoposide
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Tucatinib
Olaparib {u} may lead to a major life threatening interaction when taken with {v} Voriconazole
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Olaparib may lead to a major life threatening interaction when taken with Tucatinib
Olaparib may lead to a major life threatening interaction when taken with Voriconazole